Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study

Autor: Kasper Bonnesen, Lars Pedersen, Vera Ehrenstein, Marie Stjerne Grønkjær, Henrik Toft Sørensen, Jesper Hallas, Timothy Lee Lash, Morten Schmidt

Publikováno v: Bonnesen, K, Pedersen, L, Ehrenstein, V, Grønkjær, M S, Sørensen, H T, Hallas, J, Lash, T L & Schmidt, M 2023, ' Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events : A Case-Crossover Study ', Drug Safety, vol. 46, no. 6, pp. 533-543 . https://doi.org/10.1007/s40264-023-01298-0

Introduction: It is unknown whether the cardiovascular risks associated with non-steroidal anti-inflammatory drug (NSAID) use differ according to lifestyle and socioeconomic position. Objective: We examined the association between NSAID use and major

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1512efa394944f8b5bef272ad0084d97
https://doi.org/10.1007/s40264-023-01298-0

The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events

Autor: Christopher Rohde, Søren Dinesen Østergaard

Publikováno v: Østergaard, S D & Rohde, C 2023, ' The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events ', Acta Neuropsychiatrica, vol. 35, no. 1, pp. 1-5 . https://doi.org/10.1017/neu.2022.36

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae55ae24d96f5eda612a1ed5833dfff8
https://pure.au.dk/portal/da/publications/the-use-of-lowdose-quetiapine-does-not-necessarily-increase-the-risk-of-major-adverse-cardiovascular-events(e11aa16e-38f8-47a7-9398-fd834a20c3de).html

Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort

Autor: Laaboub, N., Dubath, C., Ranjbar, S., Sibailly, G., Grosu, C., Piras, M., Délessert, D., Richard-Lepouriel, H., Ansermot, N., Crettol, S., Vandenberghe, F., Grandjean, C., Delacrétaz, A., Gamma, F., Plessen, K.J., von Gunten, A., Conus, P., Eap, C.B.

Publikováno v: BMC psychiatry, vol. 22, no. 1, pp. 342

Insomnia disorders as well as cardiometabolic disorders are highly prevalent in the psychiatric population compared to the general population. We aimed to investigate their association and evolution over time in a Swiss psychiatric cohort. Data for 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::9049b42d2e2477128e870be37850e64f
https://serval.unil.ch/resource/serval:BIB_2E9824076089.P001/REF.pdf

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Autor: Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri, Jonathan E Shaw, Jenni Ilomäki, Avraham Karasik, Su-Yen Goh, Chern-En Chiang, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, Mikhail Kosiborod, John P Wilding, Kamlesh Khunti, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Luis Alberto García Rodríguez, Jonathan Shaw, Suzanne Arnold, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer-Cohen, Reid Whitlock, Lucia Cea-Soriano, Oscar Fernándex Cantero, Jordan A. Menzin, Matthew Guthrie, Jennie Ilomaki, Dianna Magliano

Publikováno v: Kohsaka, S, Lam, C S P, Kim, D J, Cavender, M A, Norhammar, A, Jørgensen, M E, Birkeland, K, Holl, R W, Franch-Nadal, J, Tangri, N, Shaw, J, Ilomäki, J, Karasik, A, Goh, S Y, Chiang, C E, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P & Kosiborod, M 2020, ' Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors : an analysis from the CVD-REAL 2 multinational cohort study ', The Lancet Diabetes and Endocrinology, vol. 8, no. 7, pp. 606-615 . https://doi.org/10.1016/S2213-8587(20)30130-3
Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC

Background: Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68860c6556bbf38e0e25d66268d78e6f
https://doi.org/10.1016/s2213-8587(20)30130-3

Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]

Autor: Lu, H., Hullin, R., Yerly, P., Meyer, P., Kosinski, C., Daux, A.

Publikováno v: Revue medicale suisse, vol. 17, no. 740, pp. 1034-1038

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::68472c38c8f1eb8f3f7a8a91d41b1767
https://serval.unil.ch/resource/serval:BIB_7FA860CBBECC.P001/REF.pdf